Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia

NCT00105521 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT00105521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00105521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia
Lead sponsor
EMD Serono
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2004
Completion date
March 31, 2006
Enrollment
398 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

dyskinesia, parkinson's disease